Acorda Therapeutics, Inc. (NASDAQ:ACOR) went up to recover about 35.85% since recording its record low price of $12.86. The stock experienced 2.89% jump, arriving at $17.47 on 01/10/2019. During the day, the stock price traveled from $16.36 to $17.55. This company shares are 25.3% off its target price of $21.89 and the current market capitalization stands at $824.3M. The recent change has given its price a -2.46% deficit over SMA 50 and -51.94% deficit over its 52-week high. The stock witnessed -8.2% declines, 6.78% gains and -40.68% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACOR’s volatility during a week at 6.28% and during a month it has been found around 7.8%.Acorda Therapeutics, Inc. (ACOR) Top Holders
Institutional investors currently hold around $861 million or 0% in ACOR stock. Look at its top three institutional owners. Scopia Capital Management Lp owns $120.68 million in Acorda Therapeutics, Inc., which represents roughly 14.64% of the company’s market cap and approximately 14.02% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 6,911,813 shares of the stock are valued at $117.36 million. The third largest holder is Blackrock Inc., which currently holds $99.18 million worth of this stock and that ownership represents nearly 12.03% of its market capitalization.Acorda Therapeutics, Inc. 13F Filings
At the end of September reporting period, 81 institutional holders increased their position in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by some 6,817,849 shares, 86 decreased positions by 4,623,181 and 35 held positions by 39,278,429. That puts total institutional holdings at 50,719,459 shares, according to SEC filings. The stock grabbed 23 new institutional investments totaling 847,515 shares while 25 institutional investors sold out their entire positions totaling 867,827 shares.Acorda Therapeutics, Inc. (NASDAQ:ACOR) Insider Trades
Multiple company employees have indulged in significant insider trading. Acorda Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Scopia Capital Management Lp has sold 134,174 shares of Acorda Therapeutics, Inc. (ACOR) in trading session dated Jan. 08, 2019. These shares are worth $2,203,137 and were traded at $16.42 each. The SEC filing shows that Scopia Capital Management Lp performed a sale of 55,207 shares. The 10% Owner disposed these shares by way of transaction on Jan. 04, 2019. The company’s shares were given away at $16.24 per share worth to an income of some $896,562 on account of Scopia Capital Management Lp.
10% Owner, Scopia Capital Management Lp, sold 52,891 common shares of Acorda Therapeutics, Inc. (ACOR) in the open market. In a transaction dated Dec. 28, 2018, the shares were put up for sale at an average price of $14.99, raking in a sum of $792,836. After this sale, 5,491,035 common shares of ACOR are directly owned by the insider, with total stake valued at $95,928,381.
In the transaction dated Dec. 27, 2018, the great number of shares disposed came courtesy the 10% Owner; Scopia Capital Management Lp disposed a total of 100,000 shares at an average price of $14.66, amounting to approximately $1,466,000. The insider now directly owns 5,543,926 shares worth $96,852,387.Acorda Therapeutics, Inc. (ACOR) Analyst Guide
Several analysts have released their opinion on Acorda Therapeutics, Inc. (NASDAQ:ACOR), with 0 analysts believing it is a strong buy. Whereas 5 of them predict the stock is a hold. Also, there are 2 buy, 2 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation.